Works matching IS 10837159 AND DT 2022 AND VI 27 AND IP 5
Results: 22
Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. e406, doi. 10.1093/oncolo/oyac037
- By:
- Publication type:
- Article
Stepping Down, Looking Forward.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 335, doi. 10.1093/oncolo/oyac073
- By:
- Publication type:
- Article
Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 336, doi. 10.1093/oncolo/oyac070
- By:
- Publication type:
- Article
In Reply.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 398, doi. 10.1093/oncolo/oyac038
- By:
- Publication type:
- Article
Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 352, doi. 10.1093/oncolo/oyac047
- By:
- Publication type:
- Article
On Crying.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 424, doi. 10.1093/oncolo/oyac043
- By:
- Publication type:
- Article
"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. e393, doi. 10.1093/oncolo/oyac039
- By:
- Publication type:
- Article
Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. e410, doi. 10.1093/oncolo/oyac056
- By:
- Publication type:
- Article
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 344, doi. 10.1093/oncolo/oyac050
- By:
- Publication type:
- Article
Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 389, doi. 10.1093/oncolo/oyac034
- By:
- Publication type:
- Article
Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. e402, doi. 10.1093/oncolo/oyac033
- By:
- Publication type:
- Article
Comparing Barriers and Facilitators to Adolescent and Young Adult Clinical Trial Enrollment Across High- and Low-Enrolling Community-Based Clinics.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 363, doi. 10.1093/oncolo/oyac030
- By:
- Publication type:
- Article
Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 380, doi. 10.1093/oncolo/oyac025
- By:
- Publication type:
- Article
Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 414, doi. 10.1093/oncolo/oyac023
- By:
- Publication type:
- Article
Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 407, doi. 10.1093/oncolo/oyac021
- By:
- Publication type:
- Article
Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. e384, doi. 10.1093/oncolo/oyab067
- By:
- Publication type:
- Article
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 342, doi. 10.1093/oncolo/oyab066
- By:
- Publication type:
- Article
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 338, doi. 10.1093/oncolo/oyab065
- By:
- Publication type:
- Article
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 340, doi. 10.1093/oncolo/oyab062
- By:
- Publication type:
- Article
Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 371, doi. 10.1093/oncolo/oyab030
- By:
- Publication type:
- Article